The FDA has officially expanded the therapeutic usage of Genentech’s satralizumab (Enspryng) to treat patients suffering from Thyroid Eye Disease (TED). Marking a massive shift in clinical ophthalmology, Enspryng is the first subcutaneous treatment option approved for this painful, disfiguring autoimmune condition. Boasting an excellent safety profile, the drug allows individuals the unique opportunity for convenient at-home administration, vastly improving the quality of life for patients who previously faced very limited, highly invasive healthcare options.
About the Author
